A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
Sixteen patients with advanced and recurrent malignant salivary gland tumours were admitted to a randomised trial and the response assessed. Seven patients received Epirubicin/5-Fluorouracil and none of these patients responded. Nine patients received Cisplatinum and only one patient had a partial response. The trial suggests that chemotherapy has no place in the treatment of advanced salivary gland malignant tumours.
Jones
A S
AS
Department of Otorhinolaryngology, University of Liverpool, UK.
Phillips
D E
DE
Cook
J A
JA
Helliwell
T R
TR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D012468:Salivary Gland Neoplasms / Q000188:drug therapy*
D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil